Boltz Expands AI Drug Discovery Reach with Takeda Collaboration

Boltz has entered a strategic partnership with Takeda to deploy its biomolecular AI models across the Japanese pharmaceutical company’s discovery organisation, strengthening its position in the rapidly expanding field of AI-enabled drug design.

The deal follows Boltz’s recent launch with $28 million in seed funding and an earlier partnership with Pfizer, marking another step in its push to embed foundation model technology into mainstream pharmaceutical R&D workflows.

The collaboration will give Takeda scientists direct access to Boltz’s latest biomolecular models, designed to improve prediction of molecular structures and accelerate the identification of novel drug candidates.

Embedding Foundation Models into Drug Discovery Workflows

Under the agreement, Takeda will integrate Boltz’s platform into its internal research environment through user interfaces, APIs and agent-based integrations.

This setup allows scientists from across disciplines, including machine learning, computational biology, medicinal chemistry and protein engineering, to interact with the models using natural language and structured computational tools.

Boltz CEO Gabriele Corso said the aim is to make advanced biomolecular modelling more accessible and usable across discovery teams, enabling faster iteration and more informed decision-making in early-stage drug development.

The partnership includes access to two core systems: BoltzMol-1, focused on small-molecule hit discovery, and BoltzProt-1, designed for protein engineering and design.

Early Validation Across Multiple Targets

Boltz has highlighted early validation results for its models across both small-molecule and biologics applications.

BoltzMol-1 reportedly identified confirmed hits across six of ten tested targets while screening only 28 to 51 compounds per target. In parallel, BoltzProt-1 demonstrated improved performance in de novo nanobody design, achieving nearly triple the hit rate of its earlier generation model across benchmark targets.

These results reflect growing industry interest in AI systems that can reduce experimental burden while increasing hit identification efficiency in early discovery.

Integrating AI Directly into R&D Decision-Making

A key feature of the collaboration is the integration of Boltz’s platform into Takeda’s existing discovery infrastructure via APIs and workflow tools.

The system is designed to function alongside large language model agents, allowing researchers to run predictive and generative modelling tasks using natural language prompts.

Boltz scientists will also collaborate directly with Takeda teams on selected programmes, supporting model fine-tuning for specific biological targets.

While financial terms of the deal were not disclosed, Takeda will retain full ownership of any compounds generated using Boltz’s technology.

Takeda Continues to Scale Its AI Strategy

The agreement is part of Takeda’s broader expansion into AI-driven drug discovery. The company has recently also entered into a collaboration with Iambic, potentially worth more than $1.7 billion, focused on small-molecule discovery across oncology, gastrointestinal and inflammatory disease areas.

Together, these partnerships highlight Takeda’s increasing reliance on external AI platforms to accelerate discovery across multiple therapeutic domains.

A Growing Role for Foundation Models in Pharma R&D

The Boltz–Takeda collaboration reflects a wider shift in pharmaceutical research, where foundation models are increasingly being embedded directly into discovery pipelines.

Rather than acting as standalone tools, these systems are being integrated into day-to-day scientific workflows, enabling real-time prediction, design and prioritisation of drug candidates.

As competition intensifies in AI-driven drug discovery, partnerships like this are likely to become a core mechanism for combining computational innovation with large-scale pharmaceutical development capabilities.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com